AP-HP and UPMC has come to embody French excellence in science and medicine. It carries out high-level research, as attested by the numerous international prizes and awards it has received and its collaborations with more than a hundred overseas universities. The Pierre-et-Marie Curie Faculty of Medicine (Salpêtrière) is the premier university teaching hospital in Europe. The Institute for Memory and Alzheimer Disease (IM2A) is dedicated to clinical research on dementia constituting an interface between research and care for patients and families and is at the forefront of dementia care and research resulting from long-term involvement of neurologists and specialists at the neuroimaging and nuclear medicine units. IM2A includes a clinical trial centre, the National Reference Center for Rare Dementias and the Regional Memory Centre.
The Paris group will be led by Prof. Bruno Dubois, director of the Behavioural Neurology Department and of the Dementia Research Centre at the Salpêtrière Hospital. Professor Dubois coordinates the National Reference Centre on Rare Dementias and the national Reference Centre for Young Onset Alzheimer Patients. He is president of the scientific committee of the French Alzheimer’s Association and a member of EADC. Professor Dubois is an internationally recognised expert in the field of dementia. He has acted as a principal investigator in numerous pharmacological trials in AD and has also made significant contributions to the methodology of such trials. Recently he initiated the formulation of novel diagnostic criteria for AD. Furthermore, Professor Dubois has special interest in FTLD and in rare neurological disorders that can cause YOD. Thierry Hergueta is a clinical psychologist and will act as an investigator, with junior researchers Sarah Boucault and Anna Metcalfe. The group is supported by Professor Dubois’ assistant, Carole Metais.
Role in the consortium
AP-HP/UPMC leads WP5 and is partner in WP2, WP3 and WP4.